Published in AIDS on May 11, 2007
Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ (2008) 4.54
Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med (2009) 4.34
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One (2008) 3.13
Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav (2010) 3.08
Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr (2011) 2.32
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr (2009) 2.26
Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One (2010) 2.24
Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One (2011) 2.11
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One (2010) 2.05
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ (2009) 1.98
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS (2008) 1.85
Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses (2008) 1.84
Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: a prospective cohort study. PLoS One (2010) 1.79
Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis (2011) 1.77
Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One (2010) 1.77
Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med (2014) 1.69
Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. JAMA Oncol (2015) 1.55
Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis (2010) 1.49
HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis (2012) 1.47
Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS (2010) 1.43
Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS (2012) 1.42
Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health (2011) 1.37
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis (2012) 1.36
Integrating antiretroviral therapy into antenatal care and maternal and child health settings: a systematic review and meta-analysis. Bull World Health Organ (2012) 1.35
Spending more to save more: interventions to promote adherence. Ann Intern Med (2010) 1.34
Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic review. AIDS Behav (2014) 1.31
Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open (2013) 1.29
Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc (2009) 1.25
HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS (2008) 1.24
Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc (2011) 1.24
Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association "Espoir Vie Togo" in Togo, West Africa. BMC Clin Pharmacol (2010) 1.18
The consequences of post-election violence on antiretroviral HIV therapy in Kenya. AIDS Care (2011) 1.17
Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother (2011) 1.17
Population-based monitoring of HIV drug resistance in Namibia with early warning indicators. J Acquir Immune Defic Syndr (2010) 1.15
Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions. AIDS Behav (2008) 1.14
Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program. Clin Infect Dis (2012) 1.10
Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS One (2012) 1.10
Knowledge, attitudes, and practice of tuberculosis among Maasai in Simanjiro district, Tanzania. Am J Trop Med Hyg (2010) 1.07
Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. BMC Public Health (2010) 1.04
Psychological distress and adherence to highly active anti-retroviral therapy (HAART) in Uganda: a pilot study. Afr Health Sci (2009) 1.03
A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi. Clin Infect Dis (2012) 1.02
Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health (2015) 1.00
The importance of social ties in sustaining medication adherence in resource-limited settings. J Gen Intern Med (2011) 1.00
Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda. J Acquir Immune Defic Syndr (2015) 1.00
Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in Namibia. PLoS One (2013) 0.97
Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA. J Acquir Immune Defic Syndr (2012) 0.97
Adherence to HIV care after pregnancy among women in sub-Saharan Africa: falling off the cliff of the treatment cascade. Curr HIV/AIDS Rep (2015) 0.96
Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health (2014) 0.96
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. PLoS One (2008) 0.95
High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend (2013) 0.95
HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods. J Acquir Immune Defic Syndr (2016) 0.94
Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa. AIDS Patient Care STDS (2011) 0.94
HIV drug resistance early warning indicators in namibia with updated World Health Organization guidance. PLoS One (2014) 0.94
Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these? Global Health (2010) 0.93
Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. Int J Tuberc Lung Dis (2016) 0.93
Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia. AIDS (2015) 0.90
Predictors of raised viral load during antiretroviral therapy in patients with and without prior antiretroviral use: a cross-sectional study. PLoS One (2013) 0.90
Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review. PLoS One (2013) 0.89
A paradigm shift to prevent HIV drug resistance. PLoS Med (2008) 0.88
Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in Cambodia. AIDS Res Treat (2009) 0.88
Treatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South Africa. PLoS One (2011) 0.88
Risk factors for suboptimal antiretroviral therapy adherence in HIV-infected adolescents in Gaborone, Botswana: a pilot cross-sectional study. Patient Prefer Adherence (2013) 0.87
HIV drug resistance early warning indicators in Namibia for public health action. PLoS One (2013) 0.85
Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya. J Int AIDS Soc (2014) 0.84
Shamba Maisha: Pilot agricultural intervention for food security and HIV health outcomes in Kenya: design, methods, baseline results and process evaluation of a cluster-randomized controlled trial. Springerplus (2015) 0.84
Adherence to antiretroviral therapy in resource-limited settings: everything matters. AIDS (2007) 0.84
Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies. J Acquir Immune Defic Syndr (2012) 0.84
The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention. Infect Disord Drug Targets (2011) 0.84
Prevalence of drug-resistant HIV-1 in rural areas of Hubei province in the People's Republic of China. J Acquir Immune Defic Syndr (2009) 0.83
Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study. AIDS Behav (2015) 0.83
Stock-outs of antiretroviral drugs and coping strategies used to prevent changes in treatment regimens in Kinondoni District, Tanzania: a cross-sectional study. J Pharm Policy Pract (2014) 0.82
Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring. J Acquir Immune Defic Syndr (2015) 0.82
Feasibility and acceptability of mobile phone short message service as a support for patients receiving antiretroviral therapy in rural Uganda: a cross-sectional study. J Int AIDS Soc (2015) 0.81
Costs of providing food assistance to HIV/AIDS patients in Sofala province, Mozambique: a retrospective analysis. Cost Eff Resour Alloc (2013) 0.81
Characterizing retention in HAART as a recurrent event process: insights into 'cascade churn'. AIDS (2015) 0.81
Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. J Acquir Immune Defic Syndr (2015) 0.81
Dissemination of research findings to research participants living with HIV in rural Uganda: challenges and rewards. PLoS Med (2013) 0.81
Reasons for Missing Antiretroviral Therapy: Results from a Multi-Country Study in Tanzania, Uganda, and Zambia. PLoS One (2016) 0.81
How HIV treatment could result in effective prevention. Future Virol (2010) 0.80
Harm reduction and equity of access to care for French prisoners: a review. Harm Reduct J (2008) 0.80
Determinants of utilization of a no-cost HIV transition clinic: a cross-sectional study of young adults living with HIV/AIDS. Adolesc Health Med Ther (2014) 0.80
The 90 90 90 strategy to end the HIV Pandemic by 2030: Can the supply chain handle it? J Int AIDS Soc (2016) 0.79
Rate and predictors of employment among formerly polysubstance dependent urban individuals in recovery. J Addict Dis (2012) 0.79
Understanding reasons for treatment interruption amongst patients on antiretroviral therapy--a qualitative study at the Lighthouse Clinic, Lilongwe, Malawi. Glob Health Action (2014) 0.78
Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART. BMC Infect Dis (2013) 0.78
Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review. BMJ Glob Health (2016) 0.78
CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy. AIDS Res Treat (2011) 0.77
Combined antiretroviral and anti-tuberculosis drug resistance following incarceration. South Afr J HIV Med (2013) 0.77
'Forced treatment interruptions' and risk of HIV resistance in countries adopting law enforcement against marginalized populations. AIDS (2007) 0.77
Assessment of the World Health Organization's HIV Drug Resistance Early Warning Indicators in Main and Decentralized Outreach Antiretroviral Therapy Sites in Namibia. PLoS One (2016) 0.77
Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS (2013) 0.76
No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana. J Acquir Immune Defic Syndr (2013) 0.76
Lifetime HIV antiretroviral therapy adherence intervention: timing is everything: comment on "Managed problem solving for antiretroviral therapy adherence". JAMA Intern Med (2013) 0.76
Delivery of HIV care during the 2007 post-election crisis in Kenya: a case study analyzing the response of the Academic Model Providing Access to Healthcare (AMPATH) program. Confl Health (2013) 0.75
The adherence-outcome relationship is not altered by diary-driven adjustments of microelectronic monitor data. Pharmacoepidemiol Drug Saf (2015) 0.75
Free HIV antiretroviral therapy enhances adherence among individuals on stable treatment: implications for potential shortfalls in free antiretroviral therapy. PLoS One (2013) 0.75
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis (2005) 12.59
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med (2006) 8.57
Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med (2009) 8.26
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04
Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet (2009) 6.80
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis (2011) 5.94
Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet (2002) 5.80
Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (2003) 5.52
Untreated gonococcal and chlamydial infection in a probability sample of adults. JAMA (2002) 5.07
Hormonal contraception and the risk of HIV acquisition. AIDS (2007) 5.05
Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns. PLoS Med (2006) 4.86
Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 4.58
Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (2009) 4.54
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet (2005) 4.51
Food insufficiency is associated with high-risk sexual behavior among women in Botswana and Swaziland. PLoS Med (2007) 4.48
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) (2008) 4.38
Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med (2009) 4.34
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (2012) 4.26
HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS (2011) 4.26
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr (2010) 4.20
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis (2008) 3.98
Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med (2010) 3.84
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials (2004) 3.75
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis (2002) 3.53
Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS (2009) 3.53
Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet (2011) 3.52
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44
Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav (2009) 3.39
Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol (2004) 3.36
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis (2007) 3.16
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis (2011) 3.16
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One (2008) 3.13
Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav (2010) 3.08
Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc (2013) 3.00
Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol (2005) 3.00
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2009) 2.99
Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97
HIV seroprevalence among homeless and marginally housed adults in San Francisco. Am J Public Health (2004) 2.96
A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis (2006) 2.92
Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav (2009) 2.86
Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr (2011) 2.80
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis (2003) 2.72
Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis (2010) 2.70
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. AIDS (2012) 2.63
Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda. J Acquir Immune Defic Syndr (2009) 2.62
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS (2003) 2.60
Expanding HIV care in Africa: making men matter. Lancet (2009) 2.54
Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS One (2010) 2.53
Antiretroviral therapy is associated with increased fertility desire, but not pregnancy or live birth, among HIV+ women in an early HIV treatment program in rural Uganda. AIDS Behav (2008) 2.53
Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS (2003) 2.52
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis (2007) 2.51
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS (2005) 2.48
Responding to the human resource crisis: peer health workers, mobile phones, and HIV care in Rakai, Uganda. AIDS Patient Care STDS (2008) 2.48
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (2011) 2.43
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39
Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet (2002) 2.36
Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis (2004) 2.33